Regeneron/Sanofi's Praluent drug pricing and market rollout
Regeneron/Sanofi's Praluent drug pricing and market rollout The passage only discusses the medical benefits, pricing, and market competition of a new cholesterol drug, with no mention of influential political actors, financial misconduct, or investigative leads. It provides general industry information rather than actionable leads. Key insights: Praluent targets PCSK9 and can lower LDL by up to 60%; Wholesale cost projected at $40 per day ($14,600 per year); Regeneron and Sanofi expect insurer rebates to offset price
Summary
Regeneron/Sanofi's Praluent drug pricing and market rollout The passage only discusses the medical benefits, pricing, and market competition of a new cholesterol drug, with no mention of influential political actors, financial misconduct, or investigative leads. It provides general industry information rather than actionable leads. Key insights: Praluent targets PCSK9 and can lower LDL by up to 60%; Wholesale cost projected at $40 per day ($14,600 per year); Regeneron and Sanofi expect insurer rebates to offset price
Tags
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.